References
1. Rawla P. Epidemiology of Prostate Cancer. World JJournal
Oncol . 2019;10(2):63-89. doi:10.14740/wjon1191
2. Castillejos-molina RA, Gabilondo-navarro FB. Prostate cancer.Salud Publica Mex . 2016;58(2):279-284.
3. Torres-Sánchez LE, Espinoza-Giacinto R, Rojas-Martínez R, et al.
Prostate cancer mortality according to marginalization status in Mexican
states from 1980 to 2013. Salud Publica Mex . 2016;58(2):179-186.
doi:10.21149/spm.v58i2.7787
4. Reynoso-Noverón N, Torres-Domínguez JA. Epidemiología del cáncer en
México : carga global y proyecciones 2000-2020 Epidemiology of cancer
in México : global burden and projections 2000-2020. Rev Latinoam
Med Conduct . 2017;8(1):9-15.
5. Gomez-Guerra LS, Martinez-Fierro ML, Alcantara-Aragon V, et al.
Population based prostate cancer screening in north Mexico reveals a
high prevalence of aggressive tumors in detected cases. BMC
Cancer . 2009;9(91):1-6. doi:10.1186/1471-2407-9-91
6. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening
in the randomized prostate, lung, colorectal, and ovarian cancer
screening trial: Mortality results after 13 years of follow-up. J
Natl Cancer Inst . 2012;104(2):125-132. doi:10.1093/jnci/djr500
7. Schroder FH, Hugosson J, Roobol MJ, et al. The European Randomized
Study of Screening for Prostate Cancer – Prostate Cancer Mortality at
13 Years of Follow-up. Lancet . 2014;384(9959):2027-2035.
doi:10.1016/S0140-6736(14)60525-0.The
8. Tsodikov, Alex. Gulati, Roman. Heijnsdijk, Eveline AM. Pinsky, Paul
F. Moss SM. Reconciling the effects of screening on prostate cancer
mortality in the ERSPC and PLCO trials. Ann Intern Med .
2015;167(7):449-455. doi:10.1038/ncomms5930.Genetic
9. Carter HB, Albertsen PC, Barry MJ, et al. Early Detection of Prostate
Cancer: AUA Guideline. J Urol . 2013;190(2):419-426.
doi:10.1016/j.juro.2013.04.119
10. Drummond FJ, Carsin A-E, Sharp L, Comber H. Factors prompting
PSA-testing of asymptomatic men in a country with no guidelines: a
national survey of general practitioners. BMC Fam Pract .
2009;10(1):3. doi:10.1186/1471-2296-10-3
11. Tasian GE, Cooperberg MR, Cowan JE, et al. Prostate specific antigen
screening for prostate cancer: Knowledge of, attitudes towards, and
utilization among primary care physicians. Urol Oncol Semin Orig
Investig . 2012;30(2):155-160. doi:10.1016/j.urolonc.2009.12.019
12. Brett J, Watson E, Hewitson P, et al. PSA testing for prostate
cancer: An online survey of the views and reported practice of General
Practitioners in the UK. BMC Fam Pract . 2005;6:1-6.
doi:10.1186/1471-2296-6-24
13. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review
and meta-analysis of tobacco use and prostate cancer mortality and
incidence in prospective cohort studies. Eur Urol .
2014;66(6):1054-1064. doi:10.1016/j.eururo.2014.08.059
14. Zhang L, Wang Y, Qin Z, et al. Correlation between prostatitis,
benign prostatic hyperplasia and prostate cancer: A systematic review
and meta-analysis. J Cancer . 2020;11(1):177-189.
doi:10.7150/jca.37235
15. Catalona WJ, Richie JP, Ahman FR, et al. Comparison of digital
rectal examination and serum prostate specific antigen in the early
detection of prostate cancer: results of a multicenter clinical trial of
6,630 men. J Urol . 2017;197(25):S200-S207.
16. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in
Cancer Prostate. Indian J Surg Oncol . 2012;3(2):120-129.
doi:10.1007/s13193-012-0142-6
17. Tun Firzara AM, Ng CJ. Knowledge and practice of prostate cancer
screening among general practitioners in Malaysia: a cross-sectional
study. BMJ Open . 2016;6(9):1-7. doi:10.1136/bmjopen-2016-011467
18. Lajous M, Cooperberg MR, Rider J, et al. Prostate cancer screening
in low- and middle- income countries: the Mexican case. Salud
Publica Mex . 2019;61(4):542. doi:10.21149/10373
Table 1 . Primary Care Physicians’ characteristics and practice
trends related to prostate cancer early detection.